{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Buffer&page=14",
    "query": {
      "intervention": "Buffer",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 508,
    "total_pages": 51,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Buffer&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Buffer&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T18:50:12.596Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03102190",
      "title": "Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sinusitis",
        "Nasal Polyps"
      ],
      "interventions": [
        {
          "name": "Verapamil Hydrochloride Intranasal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Benjamin Bleier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 6,
      "start_date": "2017-06-05",
      "completion_date": "2018-03-26",
      "has_results": true,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-10-24T18:50:12.596Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03102190"
    },
    {
      "nct_id": "NCT01684410",
      "title": "Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Alpha-1 HC 100 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alpha-1 HC 200 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-08",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2016-02-08",
      "last_synced_at": "2026-10-24T18:50:12.596Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01684410"
    },
    {
      "nct_id": "NCT05737121",
      "title": "Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Cystitis",
        "Bladder Pain Syndrome"
      ],
      "interventions": [
        {
          "name": "VNX001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lidocaine",
          "type": "DRUG"
        },
        {
          "name": "Heparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vaneltix Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2023-05-22",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-24T18:50:12.596Z",
      "location_count": 14,
      "location_summary": "Escondido, California • Los Angeles, California • Newport Beach, California + 10 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05737121"
    },
    {
      "nct_id": "NCT03318315",
      "title": "Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Avian Influenza",
        "Influenza",
        "Influenza Immunisation"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "Inactivated influenza H7N9 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Virus Quadrivalent Inactivated Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate Buffered Saline (PBS) diluent",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "19 Years to 64 Years"
      },
      "enrollment_count": 149,
      "start_date": "2018-02-20",
      "completion_date": "2019-07-25",
      "has_results": true,
      "last_update_posted_date": "2020-08-06",
      "last_synced_at": "2026-10-24T18:50:12.596Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03318315"
    },
    {
      "nct_id": "NCT00768066",
      "title": "The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stem Cell Transplantation",
        "Ventricular Dysfunction, Left"
      ],
      "interventions": [
        {
          "name": "Autologous human mesenchymal cells (hMSCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous human bone marrow cells (hBMCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 65,
      "start_date": "2008-08",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-12-14",
      "last_synced_at": "2026-10-24T18:50:12.596Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00768066"
    },
    {
      "nct_id": "NCT05010577",
      "title": "Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Pseudomonas Aeruginosa Infection",
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "BX004-A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BiomX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2022-06-21",
      "completion_date": "2024-03-10",
      "has_results": false,
      "last_update_posted_date": "2025-07-18",
      "last_synced_at": "2026-10-24T18:50:12.596Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05010577"
    },
    {
      "nct_id": "NCT02823002",
      "title": "Pain Perception: Lidocaine Rate/Temp/Buffer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Slow, Room Temperature Injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Rapid, Room Temperature Injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Slow, Warm Temperature Injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Rapid, Warm Temperature Injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Buffered Injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Non-Buffered Injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Lidocaine",
          "type": "DRUG"
        },
        {
          "name": "Buffer",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 26,
      "start_date": "2016-06",
      "completion_date": "2025-01",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-10-24T18:50:12.596Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02823002"
    },
    {
      "nct_id": "NCT00500747",
      "title": "Chiron Corp HCV E1/E2 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "HCV E1E2/MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 60,
      "start_date": "2003-08",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2011-06-10",
      "last_synced_at": "2026-10-24T18:50:12.596Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00500747"
    },
    {
      "nct_id": "NCT07815574",
      "title": "iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma (Skin Cancer)",
        "Advanced Melanoma",
        "Metastatic Melanoma",
        "Skin Cancer"
      ],
      "interventions": [
        {
          "name": "iSCIB1+",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab & Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Scancell Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2026-12-01",
      "completion_date": "2032-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-24T18:50:12.596Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07815574"
    },
    {
      "nct_id": "NCT03981952",
      "title": "Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Risk Reduction"
      ],
      "interventions": [
        {
          "name": "Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent Invasive Salmonella Disease Vaccine (12 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent Invasive Salmonella Disease Vaccine (25 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 96,
      "start_date": "2019-10-28",
      "completion_date": "2021-05-07",
      "has_results": false,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-10-24T18:50:12.596Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03981952"
    }
  ]
}